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Aim: Steatosis is a common histological feature of chronic
liver disease, especially alcoholic and non-alcoholic fatty liver
disease, as well as chronic hepatitis C. A recent study showed
that evaluating the controlled attenuation parameter (CAP)
with transient elastography was an efﬁcient way of non-
invasively determining the severity of hepatic steatosis. The
objective of this study was to prospectively evaluate the
utility of CAP for diagnosing steatosis in patients with chronic
liver disease.
Methods: One hundred and ﬁfty-ﬁve consecutive patients
with suspected chronic liver disease underwent steatosis
diagnosis using CAP, blood sample analyses, computed
tomography for assessing the liver/spleen ratio and liver
biopsy. Steatosis was graded according to the percentage of
fat-containing hepatocytes: S0, less than 5%; S1, 5–33%; S2,
34–66%; and S3: more than 66%.
Results: The CAP was signiﬁcantly correlated with steatosis
grade, and there were signiﬁcant differences between the
CAP value of the S0 patients and those of the patients with
other grades of steatosis. S0 and S1–3 hepatic steatosis
were considered to represent mild and signiﬁcant steatosis,
respectively. The CAP values of the patients with mild and
signiﬁcant steatosis were signiﬁcantly different (P < 0.0001).
The area under the receiver–operator curve (AUROC) value of
the CAP for diagnosing signiﬁcant steatosis was 0.878 (95%
conﬁdence interval, 0.818–0.939), and the optimal CAP cut-off
value for detecting signiﬁcant steatosis was 232.5 db/m. In
multivariate analysis, the CAP (P = 0.0002) and the liver to
spleen ratio (P = 0.004) were found to be signiﬁcantly associ-
ated with signiﬁcant steatosis.
Conclusion: The CAP is a promising tool for rapidly and non-
invasively diagnosing steatosis.
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INTRODUCTION
THE INCIDENCE OF obesity has markedly increasedin developed countries in the past few decades. Due
to the Westernization of lifestyles in Japan, the fre-
quency of patients presenting with non-alcoholic fatty
liver disease (NAFLD) has gradually increased, and
NAFLD/non-alcoholic steatohepatitis (NASH) is esti-
mated to affect 10 million people in the general popu-
lation.1,2 NAFLD is one of the clinical consequences of
obesity and can progress to NASH, ultimately leading to
cirrhosis, hepatocellular carcinoma and end-stage liver
failure.3,4
Liver steatosis is considered to be a risk factor for
treatment failure among patients with chronic viral
hepatitis, such as that caused by hepatitis B virus (HBV)
or hepatitis C virus (HCV).5 In addition, previous
studies demonstrated that the frequency of liver steato-
sis was significantly lower in hepatitis C patients who
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achieved a sustained virological response (SVR).6–11
Although the incidence of liver transplantation for end-
stage liver disease is increasing, there is a shortage of
organs for living donor liver transplantation.12,13 Accord-
ingly, it is important to properly estimate the degree of
liver steatosis in potential donor livers in order to ensure
the success of liver transplantation and donor safety.
Liver biopsy is the current gold standard for evaluat-
ing steatosis and other histological lesions;3,4,14 however,
it is invasive, subject to sampling error and is sometimes
painful.15,16 To avoid unnecessary biopsy examinations,
various non-invasive methods have been developed for
the assessment of hepatic steatosis.17 As fat affects ultra-
sound propagation, a novel attenuation parameter has
been developed to detect and quantify steatosis. This
parameter, which is called the controlled attenuation
parameter (CAP) because it specifically targets the liver,
is based on the ultrasonic properties of the reflected
radio frequency signals acquired by the FibroScan M
probe (Echosens, Paris, France). Although many reports
have demonstrated the utility of the CAP to determine
the extent of a patient’s liver steatosis,18–20 its utility for
assessing chronic liver disease in Japanese patients is
unknown.
The primary objective of our study was to validate the
ability of the CAP to detect and quantify steatosis. The
secondary objective was to determine whether steatosis
could be assessed simultaneously using the FibroScan M
probe in patients with biopsy-proven chronic hepatitis
due to any cause.
METHODS
Study population
ONEHUNDRED AND fifty-five consecutive patientswith suspected chronic hepatitis due to any etiol-
ogy who underwent liver biopsy and an ultrasound
examination with the FibroScan M probe on the same
day to calculate their CAP and liver stiffness measure-
ment (LSM) values were enrolled. The patients were
recruited at our institution between April and December
2012.
LSM and CAP measurement
After performing conventional ultrasonography to
search for hepatocellular carcinoma, the tip of the trans-
ducer probe was placed on the patient’s skin between
the ribs over the right lobe of the liver with the patient
lying in the dorsal decubitus position. All patients had
their CAP measured using a standard 3.5-MHz M probe.
In a preliminary retrospective study, in which the CAP
was assessed in 115 patients with chronic liver disease
due to various etiologies, the CAP performed well
during the detection and semiquantification of steato-
sis.18 The LSM was determined using a FibroScan M
probe, a Vibration-Controlled Transient Elastography
(VCTE; Echosens) device that is designed to measure
liver stiffness. Briefly, the VCTE system generates a
50-Hz shear wave that is longitudinally polarized along
the ultrasound axis.21,22 The median value of 10 mea-
surements performed at depths ranging 25–65 mm
was adopted as the final liver stiffness value and was
expressed in kPa. Only results derived from five valid
shots and displaying an interquartile range (IQR)/
median liver stiffness ratio of less than 30% were
included. The CAP was designed to measure liver ultra-
sonic attenuation (along the go and return path) at
3.5 MHz using the signals acquired by the FibroScan M
probe.18 The CAP uses a sophisticated guidance process
based on VCTE. In brief, the CAP is based on validated
measurements, which are subject to the same criteria as
the LSM and are obtained from the same signals. There-
fore, the LSM and CAP were obtained simultaneously
and in the same volume of liver parenchyma (i.e. at
depths of between 25 and 65 mm). The median of the
individual CAP values was used as the final CAP value,
which was expressed in dB/m. The ratio of the IQR of
the CAP values to the median CAP value (IQR/Mcap)
was calculated as an indicator of variability.18–20
Clinical and laboratory evaluations
Biological and clinical parameters were assessed during
liver biopsy. The following data were recorded: age; sex;
etiology; height; bodyweight; body mass index (BMI);
aspartate aminotransferase, alanine aminotransferase
(ALT), g-glutamyltransferase (GGT), total bilirubin,
albumin, triglyceride, total cholesterol, high-density
lipoprotein cholesterol, low-density lipoprotein choles-
terol, fasting glucose (FBS) and hemoglobin A1c
(HbA1c) levels; prothrombin time; and platelet count.
All blood sample analyses were performed in our hos-
pital laboratory. Liver density was assessed using the
ratio of the mean computed tomography (CT) attenua-
tion value of the liver (in Hounsfield units; HU) to that
of the spleen (L/S ratio), which was evaluated using
abdominal CT.
Liver biopsy
Liver biopsy was performed by senior surgeons using a
1.2 mm/1.6 mm diameter Menghini needle (Surecut
needle, Create Medic Co. Ltd, Japan). The liver speci-
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mens measured more than 20 mm in length and were
fixed, embedded in paraffin, and then stained with
hematoxylin and Masson-trichrome. One experienced
pathologist analyzed all of the biopsies independently
without knowledge of the clinical data. Steatosis was
graded according to the method of Kleiner et al.23 as: S0,
steatosis in less than 5% of hepatocytes; S1, 5–33%; S2,
34–66%; and S3, more than 66%
Statistical analyses
The relationships between the CAP and clinical or mor-
phological parameters were evaluated using Spearman’s
rank correlation coefficient. Multivariate analysis was
performed using multiple linear regression to investi-
gate the effects of fibrosis stage, activity grade and ste-
atosis grade on liver stiffness and the CAP. Box plots
were used to assess the utility of the non-invasive
methods for differentiating between each grade of ste-
atosis. Area under the receiver–operator curve (AUROC)
values were computed as well as their 95% confidence
intervals (CI) using the Mann–Whitney U-test statistic
according to the method proposed by Hanley and
McNeil.24 The cut-off value that maximized the accuracy,
sensitivity, and negative and positive predictive values
of the CAP for diagnosing significant steatosis was com-
puted. All statistical analyses were performed using the
SPSS software ver. 18 (SPSS, Chicago, IL, USA). Statisti-
cal results associated with P-values of less than 0.05
were considered significant.
RESULTS
Patient characteristics
THE BASELINE CHARACTERISTICS of the 155patients are shown in Table 1. The median age was
55.0 years (range, 24–91), and 92 patients were male.
Etiologies of chronic liver diseases were chronic hepati-
tis B (n = 17), chronic hepatitis C (n = 58), NASH
(n = 40), unknown etiology (n = 35) and normal liver
(n = 5). Their median BMI was 24.4 kg/m2 (range, 15.4–
39.2). The patients’ median CAP value was 231.0 dB/m
(range, 100–400) and their median LSM was 10.7 kPa
(range, 2.60–75.0). CT examinations were available in
97 patients, and the median L/S ratio of these patients
was 1.05 (range, -0.144 to 2.03).
CAP values for steatosis assessment
The CAP values of each steatosis grade are shown in
Figure 1. The median (25–75% quartiles) CAP values
for each steatosis grade were: 202.1 dB/m (range, 100–
298) for S0, 279.5 dB/m (range, 179–400) for S1,
297.7 dB/m (range, 162–367) for S2 and 323.0 dB/m
(range, 290–345) for S3. There were significant
differences between the CAP values for S0 and S1
(P < 0.0001), S0 and S2 (P < 0.0001), and S0 and S3
(P < 0.0001). A box plot of the CAP values of the
patients with mild (steatosis affecting <5% of hepato-
cytes) and significant (steatosis affecting 35% of hepa-
tocytes) hepatic steatosis is shown in Figure 2. The
median CAP value for mild hepatic steatosis was
202.1 dB/m, and that for significant hepatic steatosis
was 285.1 dB/m. There was a significant difference
between the CAP values for mild and significant hepatic
steatosis (P < 0.0001).
The AUROC of the CAP for differentiating between
mild and significant steatosis is shown in Figure 3. The
Table 1 Bioclinical and historical characteristics of the
patients
Characteristics Patient data
No. of patients 155
Age (years) 55.0 (24–91)
Sex (male/female) 92/63
Etiology (B/C/NASH/others) 17/58/40/40
Height (m) 1.61 (1.40–1.79)
Bodyweight (kg) 64.0 (39.5–117.2)
Body mass index (kg/m2) 24.4 (15.4–39.2)
AST (IU/L) 52.0 (14–467)
ALT (IU/L) 64.2 (7–657)
Total bilirubin (mg/dL) 1.0 (0.3–9.3)
Serum albumin (g/dL) 4.2 (2.8–5.4)
Prothrombin (%) 93.7 (43–140)
Platelet count (¥104/mL) 19.3 (6.2–54.3)
Triglycerides (mg/dL) 113.5 (23–479)
Total cholesterol (mg/dL) 182.9 (68–336)
High-density lipoprotein cholesterol
(mg/dL)
60.5 (12–179)
Low-density lipoprotein cholesterol
(mg/dL)
113.6 (26–204)
Fasting blood sugar (mg/dL) 108.9 (21–179)
HbA1c (NGSP, %) 6.0 (4.8–10.1)
Controlled attenuation parameter
(CAP, dB/m)
231.0 (100–400)
Liver stiffness measurements
(LSM, kPa)
10.7 (2.60–75.0)
L/S ratio 1.05 (–0.144 to 2.03)
All data are median (range).
ALT, alanine aminotransferase; AST, aspartate aminotransferase;
B, HBs antigen positive; HbA1c, hemoglobin A1c; C, HCV
antibody positive; L/S, liver/spleen; NASH, non-alcoholic
steatohepatitis; NGSP, National Glycohemoglobin
Standardization Program.
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CAP displayed an AUROC value of 0.878 (95% CI,
0.818–0.939) for diagnosing significant hepatic steato-
sis. The optimal CAP cut-off value for differentiating
between mild and significant hepatic steatosis was
232.5 dB/m, which produced sensitivity and specificity
values of 87.0% and 77.2%, respectively, as well as a
positive predictive value (PPV) of 75.2% and a negative
predictive value (NPV) of 87.0%. The AUROC based on
the individual etiologies were shown in Supporting
Information Figure S1.
The results of our univariate analysis of the factors
associatedwith significant steatosis are shown in Table 2.
Among the analyzed factors, BMI, cholinesterase, the
CAP value and L/S ratio displayed the most significant
associations with significant steatosis (P < 0.0001).
ALT (P = 0.0001), triglyceride (P = 0.002), HbA1c (P =
0.002), alkaline phosphatase (P = 0.007), white blood
cell (P = 0.020), platelet count (P = 0.020), GGT
(P = 0.028), FBS (P = 0.036) and total cholesterol
(P = 0.043) also displayed significant associations with
significant hepatic steatosis. In the multivariate analysis,
only the CAP value (odds ratio, 27.656; 95% CI, 4.762–
160.622; P = 0.0002) and L/S ratio (odds ratio, 10.881;
95% CI, 2.101–56.361; P = 0.004) were significantly
associated with significant steatosis (Table 3).
DISCUSSION
IN JAPAN, MUCH attention has been paid to HBV/HCV-infected patients over the past few decades
because there are high numbers of carriers of these
viruses in Japan, and most cases of cirrhosis and hepa-
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Figure 1 Distribution of controlled attenuation parameter
(CAP) for each steatosis grade. The bottom and top of each box
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tile range. The line through the box indicates the median,
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Figure 3 AUROC to compare the diagnostic accuracy of liver
steatosis (<5% and 35%) assessed by controlled attenuation
parameter. AUROC, area under the receiver–operator curve;
NPV, negative predictive value; PPV, positive predictive value;
Se, sensitivity; Sp, specificity.
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tocellular carcinoma in Japan are associated with persis-
tent HBV or HCV infection.25 In recent years, NAFLD has
become a major social problem in Japan due to the
Westernization of lifestyles and the increasing rates of
obesity and diabetes.26 Approximately 30% of NAFLD
patients are considered to progress to NASH, a more
severe form of NAFLD, which leads to more advanced
fibrosis and ultimately cirrhosis.27 Among chronic viral
hepatitis patients, liver steatosis is a risk factor for infec-
tion and treatment failure.5 Chronic HCV infection is
associated with fatty liver changes, and HCV patients
display a higher incidence of fatty changes than patients
with other chronic liver dysfunctions.28,29 Furthermore,
Okanoue et al. demonstrated that the frequency of liver
steatosis was significantly lower in hepatitis C patients
who achieved an SVR.11 Therefore, it is important
to diagnose and evaluate the severity of steatosis to
improve its treatment and prognosis. Liver biopsy is the
current gold standard for evaluating steatosis and other
histological lesions;3,4,14 however, liver biopsy can be
affected by sampling error,15,16 is an invasive and often
painful procedure, and can result in severe complica-
tions.30,31 Moreover, the repetition of liver biopsy to
monitor changes in steatosis is difficult. In light of these
obstacles, various non-invasive methods have been
developed for the assessment of hepatic histology, par-
ticularly fibrosis.17,32 Steatosis can also be diagnosed by
non-invasive means and is mainly diagnosed using
conventional imaging techniques, for example, CT,
multiple resonance imaging (MRI), magnetic resonance
Table 2 Factors associated with steatosis 35% on liver biopsy (univariate analysis)
Variable Severity of hepatic steatosis P-value
<5% 35%
n Mean 1 SD n Mean 1 SD
Age <60/360 50/51 45.8 1 9.8/66.6 1 6.1 34/20 44.7 1 10.3/65.6 1 4.8 0.129
Sex Female/male 44/57 19/35 0.391
BMI (kg/m2) <25/325 74/27 21.6 1 2.0/26.8 1 1.9 18/36 23.1 1 2.0/29.3 1 4.0 <0.0001
AST (IU/L) <33/333 50/51 25.1 1 5.0/90.9 1 99.5 19/35 24.1 1 5.6/49.2 1 17.7 1.000
ALT (IU/L) <35/335 51/50 24.0 1 7.0/113.8 1 114.0 12/42 24.9 1 8.0/65.0 1 22.7 0.0001
ALP (IU/L) <359/3359 68/33 223 1 60/587 1 243 47/7 222 1 55/525 1 189 0.007
GGT (IU/L) <41/341 53/48 23.4 1 8.6/281 1 522 18/36 26.0 1 9.6/103 1 73 0.028
Cholinesterase (IU/L) <300/3300 69/32 224 1 58/339 1 35 16/38 228 1 56/381 1 50 <0.0001
Total bilirubin (mg/dL) <1.2/31.2 83/18 0.74 1 0.19/2.48 1 1.9 47/7 0.73 1 0.19/1.51 1 0.38 0.498
Serum albumin (mg/dL) <4.3/34.3 51/50 3.73 1 0.39/4.50 1 0.26 24/30 3.97 1 0.26/4.64 1 0.31 0.503
Prothrombin (%) <70/370 5/96 59.8 1 10.5/94.7 1 12.8 2/52 57.5 1 5.0/96.4 1 10.9 1.000
White blood cell (/mL) <4000/34000 25/76 3318 1 578/6143 1 1806 5/49 3522 1 485/6929 1 2836 0.020
Platelet count (/mL) <22¥104/322¥104 75/26 15.4 1 4.1/27.4 1 5.2 30/24 15.4 1 4.1/27.4 1 6.6 0.020
Triglyceride (mg/dL) <149/3149 81/13 85.9 1 28.7/182 1 46.5 32/19 82.5 1 29.7/236 1 83.8 0.002
Total cholesterol (mg/dL) <179/3179 56/45 149 1 25/213 1 33 20/34 162 1 15/212 1 22 0.043
FBS (mg/dL) <109/3109 65/33 97.7 1 6.6/141.8 1 37.0 25/27 99.3 1 6.7/133.9 1 32.0 0.036
HbA1c (NGSP, %) <6.2/36.2 63/14 5.6 1 3.7/6.5 1 0.6 26/21 5.2 1 0.3/6.9 1 1.3 0.002
CAP (dB/m) <232.5/3232.5 76/25 182 1 34/263 1 31 7/47 196 1 24/298 1 41 <0.0001
LSM (kPa) <10.7/310.7 77/24 6.0 1 1.8/29.0 1 22.0 36/18 6.1 1 2.1/15.5 1 4.6 0.255
L/S ratio 31.1/ < 1.1 40/11 1.27 1 0.16/1.01 1 0.07 13/33 1.18 1 0.08/0.74 1 0.29 <0.0001
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FBS, fasting blood
sugar; CAP, controlled attenuation parameter; GGT, g-glutamyltransferase; HbA1c, hemoglobin A1c; L/S, liver/spleen; LSM, liver
stiffness measurement; NGSP, National Glycohemoglobin Standardization Program; SD, standard deviation.
Table 3 Factors associated with steatosis 35% on liver biopsy
(multivariate analysis)
Variable Odds ratio 95% confidence
interval
P-value
CAP 3232.5 (dB/m) 27.656 4.762–160.622 0.0002
L/S ratio <1.1 10.881 2.101–56.361 0.004
Factors: body mass index, 325; alanine aminotransferase, 335;
alkaline phosphatase, 3359; g-glutamyltransferase, 341;
cholinesterase, 3300; white blood cell, 34000; platelet count,
320 ¥ 104; triglyceride, 3149; total cholesterol, 3179; fasting
blood sugar, 3109; hemoglobin A1c, 35.7; controlled attenuation
parameter (CAP), 3243.5; liver/spleen (L/S) ratio <1.1.
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spectroscopy or ultrasonography, with the latter being
the most commonly used method.33,34 However, these
techniques suffer from various pitfalls; namely,
they are costly, not easily available, operator-dependent
and/or display poor sensitivity.32,34,35 Moreover, existing
methods cannot simultaneously assess hepatic fibrosis
and steatosis. To overcome these limitations, the CAP,
which was designed to produce immediate results
and be reproducible and operator- and device-
independent, was developed.36 Previous studies have
shown the utility of the CAP for assessing the severity of
steatosis.18–21,23,37,38
In our study, we have demonstrated that the CAP is
correlated with steatosis grade and can be used to non-
invasively identify steatosis in Japanese patients. The
AUROC of the CAP for detecting significant steatosis
(35% of hepatocytes affected) was 0.878 (95% CI,
0.818–0.939), and a CAP threshold of 232.5 dB/m
demonstrated 87.0% sensitivity and 77.2% specificity
for detecting significant steatosis. This study is the first to
report the utility of the CAP in Japanese subjects. A
previous study reported similar findings in a study of
153 patients with chronic liver disease due to any etiol-
ogy, in whom the CAP displayed an AUROC of 0.81 for
diagnosing significant stenosis, and a CAP threshold of
283 dB/m demonstrated 76% sensitivity and 79% speci-
ficity for significant steatosis.20 Sasso et al. studied 115
patients with various liver disorders. As a result, they
found that the CAP displayed an AUROC of 0.91 for
detecting significant steatosis, and a CAP threshold of
238 dB/m exhibited 91% sensitivity and 81% specificity
for significant steatosis.18,19 The discrepancies between
these studies may be related to differences in the study
populations including in their disease etiologies, the
prevalence of obesity and the extent of subcutaneous
adiposity, the severity of the patients’ steatosis and racial
differences, all of which could influence CAP perfor-
mance because of spectrum bias. Further studies in
larger cohorts would help to refine the patient data char-
acteristics of the CAP.
In some patients, steatosis can progress to cirrhosis
and end-stage liver disease.39 Furthermore, liver trans-
plantation is the only treatment option for end-stage
liver failure. In such cases, it is important to select an
appropriate donor in order to achieve good donor and
recipient outcomes. The implantation of donor livers
with severe fatty infiltration is associated with a high
incidence of severe ischemic damage, resulting in
primary dysfunction and/or primary non-function after
liver transplantation.40–44 To reduce the risk of progres-
sive liver disease and achieve a successful liver transplan-
tation, it is important to estimate the extent of liver
steatosis. A few reports have suggested that there is a risk
associated with mild macrovascular steatosis after right
hepatectomy in living donors.45,46 Goldaracena et al.
reported that the liver pool can be safely expanded using
extremely marginal liver grafts. It is considered that ste-
atosis should not affect more than 30% of such grafts;12
therefore, most centers only accept donor livers from
individuals in whom hepatic steatosis affects 20% or
less of the liver.47–49 In this study, we thought that we
could detect steatosis more strictly by using a 5% cut-off
value according to Kleiner et al.23 Accordingly, we
selected 5% as the cut-off value. When we selected a
10% cut-off value, the result was similar (AUROC, 0.878
[95% CI, 0.810–0.947]; CAP threshold, 258.0 dB/m;
sensitivity, 81.8%; specificity, 87.4%).
Imaging studies such as ultrasonography, CT and MRI
can depict the characteristic features of fatty liver.30–34,39
In particular, CT has proven to be useful for diagnosing
and quantifying liver fat non-invasively. The HU attenu-
ation value of the liver on CT scans is usually higher
than that of the spleen. However, the presence of fat in
the liver will reduce its HU attenuation value. Thus, an
L/S ratio of less than 1.0 can be used to effectively
diagnose the presence of liver fat, and studies also have
shown that liver HU attenuation values of less than
40 HU represent a liver fat content of more than
30%.34,39 Furthermore, Oliva et al. reported that the use
of an L/S ratio of less than 1.2 resulted in all cases
of fatty liver being detected, whereas some authors
reported cut-off values of 1.0 or 1.1 for fatty liver.49
In our study, significant hepatic steatosis was signifi-
cantly associated with a CAP of 232.5 dB/m or more and
an L/S ratio of less than 1.1. These results demonstrate
that the CAP accurately predicts the degree of steatosis.
Furthermore, the CAP is an easier and cheaper procedure
than CT and does not involve radiation exposure.47,49,50
This study had several limitations. One limitation was
that our study involved a relatively small population,
which limited the precision of our results. Second,
although a correlation was observed between the degree
of steatosis and the CAP (r = 0.517, P < 0.0001, Pearson
product-moment correlation coefficient), our study
population was highly selected; namely, it included
patients with mild hepatic steatosis, which also limited
the precision of our results. Third, our sample size was
limited in part because of the difficulty of obtaining
valid CAP measurements in obese patients using the
FibroScan M probe. Further studies are necessary to
develop a CAP algorithm for such patients. Finally,
selection bias was another limitation of this study
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because we did not examine patients who displayed
clinical evidence of hepatic decompensation.
In conclusion, the CAP can be used for steatosis detec-
tion and semiquantification and possesses several
advantages; namely, it is non-invasive, easy to perform,
provides immediate results and is inexpensive in com-
parison with other measurement modalities. Moreover,
the CAP can provide an immediate assessment of ste-
atosis and be obtained at the same time as the LSM,
which is used to stage hepatic fibrosis. Further studies
are necessary to validate our findings in larger cohorts
and to define optimal CAP thresholds. If these results
are confirmed, the CAP could be useful for the diagnosis
of steatosis, not only in chronic liver disease, but
also in liver graft evaluations, longitudinal monitoring
of disease progression or the response to therapy,
population-based epidemiological or observational
studies, and drug discovery.
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SUPPORTING INFORMATION
ADDITIONAL SUPPORTING INFORMATION maybe found in the online version of this article at the
publisher’s website:
Figure S1 (a) AUROC to compare the diagnostic accu-
racy of liver steatosis (<5% and 35%) assessed by CAP in
HBV patients. (b) AUROC to compare the diagnostic
accuracy of liver steatosis (<5% and 35%) assessed by
CAP in HCV patients. (c) AUROC to compare the diag-
nostic accuracy of liver steatosis (<5% and 35%)
assessed by CAP in NASH patients. (d) AUROC to
compare the diagnostic accuracy of liver steatosis (<5%
and 35%) assessed by CAP in patients of other etiolo-
gies. AUROC, area under the receiver–operator curve;
CAP, controlled attenuation parameter; HBV, hepatitis B
virus; HCV, hepatitis C virus; NASH, non-alcoholic ste-
atohepatitis; NPV, negative predictive value; PPV, posi-
tive predictive value; Se, sensitivity; Sp, specificity.
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